Regenxbio Gene Therapy Trials Suspended by FDA over Safety Worries

FDA halts gene therapy trials after brain tumor found in patient

The treatments are designed to replace the genes broken in mucopolysaccharidosis type I and type II, also known as Hurler and Hunter syndromes.

Regenxbio gene therapy trials suspended by FDA over safety worries

The development of a brain tumor in a study participant led regulators to suspend a Hurler syndrome therapy in early testing and a treatment for Hunter syndrome nearing an FDA decision.

FDA puts REGENXBIO gene therapy trials on hold after brain tumour

A five-year-old patient dosed with RGX-111 has developed a brain tumour four years after being dosed with the gene therapy.The post FDA puts REGENXBIO gene therapy trials on hold after brain tumour appeared first on Clinical Trials Arena.

FDA suspends two Regenxbio gene therapy trials after patient developed brain tumor

The FDA has placed studies of two gene therapies from Regenxbio on hold after a five-year-old patient in one of the trials was found to have a brain tumor. The drug regulator's decision is a ...